ArticleBMC pulmonary medicine2021

Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.

David Slade et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.